AAJ HAS UPDATED ITS PRIVACY POLICY AND USES COOKIES ON THIS SITE. To acknowledge and accept AAJ’s privacy policy with the use of cookies, please select OK, I Accept.

Review AAJ's Privacy Policy
Litigation Groups

Abilify

The Litigation Group will educate members about Abilify and keep them apprised of the status of litigation through litigation group meetings, the group’s list server, and the sharing of materials.

Join Litigation Group

Abilify

Abilify is a widely prescribed, atypical, anti-psychotic prescription medicine developed and marketed by Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd, and various Otsuka subsidiaries. In many patients, Abilify causes uncontrollable behaviors such as compulsive gambling. The manufacturers warn about this side effect in Europe and Canada but not in the United States. Internal company documents acknowledge a plausible biological mechanism based on the long-known relationship of dopamine (upon which Abilify acts in the brain) and compulsive gambling.

The Litigation Group will educate members about Abilify and keep them apprised of the status of litigation through Litigation Group meetings, the group’s list server, and the sharing of materials.

Dues

$300 annually

Join the Conversation

Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login